Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

When Imfinzi blocks PD-L1, it stops this "hiding" process ... In this study, 54% of people were White, 41% were Asian, 1% were Black, 3% were of other races, and 17% Hispanic or Latino.

Imfinzi is a type of drug called a programmed death-ligand 1 (PD-L1) inhibitor. PD-L1 is a type of protein in your body. It prevents T-cells in the body from recognizing and attacking cancer cells.

Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and ...

AstraZeneca (NASDAQ:AZN) announced Tuesday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA) ...

Bristol Myers Squibb and AstraZeneca have quickly resolved patent infringement lawsuits around their blockbuster cancer immunotherapies. A federal judge in Delaware has approved the two companies ...

Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could ...

Consider the benefit versus risks of treatment with a PD-1/L-1 blocking antibody prior to or after an allogeneic HSCT. Based on its mechanism of action and data from animal studies, IMFINZI can ...

The open-label, randomised trial involved Imfinzi monotherapy and a regimen consisting of a single 300mg dose of Imjudo added to 1,500mg of Imfinzi ... that targets the PD-L1 protein, while ...

Bristol Myers Squibb is partnering with BioNTech on a closely watched cancer drug, in a deal worth billions of dollars.

When Imfinzi blocks PD-L1, it stops this "hiding" process ... A clinical study called TOPAZ-1 was done to test how well Imfinzi works for treating biliary tract cancer. The study also looked ...

MSD’s PD-1 inhibitor Keytruda has been approved by ... the first immunotherapy competitor to AstraZeneca’s Imfinzi for these patients. The approval was based on the KEYNOTE-966 study, which ...